Compare MPLX LP (MPLX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Neurocrine Biosciences Inc — how do they compare? MPLX LP trades at $56.75 (market cap $57.97B), while Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B). The key difference: MPLX LP is far larger — about 3.3× Neurocrine Biosciences Inc's market cap, and MPLX LP pays a 7.54% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MPLX | NBIX | |
|---|---|---|
Market Cap | $57.97B | $17.40B |
Sector | Technology | Health |
52-Week High | $59.17 | $180.55 |
52-Week Low | $47.80 | $123.10 |
Enterprise Value | $82.60B | $16.49B |
Dividend Yield | 7.54% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
